Alcon receives US FDA approval for new AcrySof® IQ ReSTOR® +2.5 Multifocal Toric IOL with ACTIVEFOCUS(TM) design for uncompromised distance vision and presbyopia correction - Seite 3
Important Information about AcrySof® IQ ReSTOR® +2.5 Multifocal Toric
IOL
Side effects associated with the AcrySof® IQ ReSTOR® +2.5 D Multifocal Toric IOL include visual disturbances such as glare, rings around lights, and blurred vision. These side effects may make it
more difficult to see while driving at night or completing tasks in low lighting such as at night or in fog, after surgery as compared to before surgery.
This IOL corrects corneal astigmatism only when it is placed in the correct position in the eye. There is a possibility that the IOL could be placed incorrectly or could move within the eye. This may result in less improvement or a reduction in vision because your corneal astigmatism has not been fully corrected, or it may cause visual symptoms.
The safety and effectiveness of the AcrySof® IQ ReSTOR® +2.5 D Multifocal Toric IOL has not been established in patients with certain eye conditions, such as glaucoma or diabetic retinopathy (an increase in eye pressure or complications of diabetes in the eye).
Lesen Sie auch
Disclaimer
The foregoing release contains forward-looking statements that can be identified by words such as "potentially," "offer," "could," "plans," "can," "may," "likely," "will," or similar terms, or by
express or implied discussions regarding potential additional marketing approvals for the AcrySof IQ ReSTOR +2.5 Multifocal Toric IOL, or regarding potential future revenues from the AcrySof IQ
ReSTOR +2.5 Multifocal Toric IOL. You should not place undue reliance on these statements. Such forward-looking statements are based on the current beliefs and expectations of management regarding
future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove
incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the AcrySof IQ ReSTOR +2.5 Multifocal Toric IOL will be
submitted or approved for sale in any additional markets, or at any particular time. Nor can there be any guarantee that the AcrySof IQ ReSTOR +2.5 Multifocal Toric IOL will be commercially
successful in the future. In particular, management's expectations regarding the AcrySof IQ ReSTOR +2.5 Multifocal Toric IOL could be affected by, among other things, the uncertainties inherent in
research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; the company's ability
to obtain or maintain proprietary intellectual property protection; general economic and industry conditions; global trends toward health care cost containment, including ongoing pricing pressures;
safety, quality or manufacturing issues, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is
providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new
information, future events or otherwise.